Home
Graduated in pharmacology and obtained a PhD in immunopharmacology from the University of Southampton. His research interests have focused on lung and joint inflammation and the cellular recruitment in asthma and arthritis. Current interests include the development of gene therapy for the treatment of arthritis and other inflammatory conditions. This research aims to combine gene therapy vectors with regulated promoter systems (responsive to pharmacological or physiological induction) to achieve long-term safe therapeutic effect in these non-fatal diseases.
Key publications
- Chernajovsky Y, Gould D, and Podhajcer OL. Genetic Interventions for the treatment of autoimmune diseases: Quo Vadis? Nature Reviews Immunology 10:800-811, (2004)
- Gould D and Chernajovsky Y. Endogenous GATA factors bind the core sequence of the tet O and influence gene regulation with the tetracycline system . Mol. Therapy, 10: 127-138, (2004).
- Gould D, Bright C and Chernajovsky Y. Inhibition of established collagen-induced arthritis with a tumour necrosis factor-alpha inhibitor expressed from a self-contained doxycycline regulated plasmid. Arthritis Res. Ther. 6: R103-R113, (2004).
- Gould D and Favorov P.Vectors for the treatment of autoimmune disease. Gene Ther. 10: 912-927, (2003).
- Chernajovsky Y, Vessillier S, Adams G, Gofur Y, M. Subang C, Annenkov A, Favorov P, Daly G and Gould D. Development of new molecules, vectors and cells for therapy of arthritis. Joint Bone Spine 70: 474-476, (2003).
- Chernajovsky Y, Dreja H, Triantaphyllopoulos K and Gould D. Interferon beta gene for the treatment of arthritis. In Methods in Molecular Biology (Vol 215): Cytokines and Colony Stimulating Factors methods and protocols. Eds. D. Korholz and W. Kiess, Humana Press, Totowa, NJ. pp. 171-180, (2003).
- Gould D. Inducible diabetes and transgene expression in a single mouse: a tool to elucidate autoimmune mechanisms. Transgenic Res. 11(6): 583-5, Dec (2002).
Search for more publications by David Gould